a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

Inclusion Criteria:

1. Signed written informed consent
2. Diagnose as Relapsed and Refractory B -ALL, and meet one of the following conditions:
3. Failed to standard chemotherapy regimens;
4. Relapse after complete remission, high-risk and / or refractory patients ;
5. Relapse after hematopoietic stem cell transplantation;
6. Evidence for cell membrane CD19 or CD22 expression
7. All genders ages: 2 to 75 years
8. The expect time of survive is above 3 months;
9. KPS>60
10. No serious mental disorders ;
11. Left ventricular ejection fraction ≥50%
12. Sufficient hepatic function defined by ALT/AST≤3 x ULN and bilirubin≤2 x ULN;
13. Sufficient renal function defined by creatinine clearance≤2 x ULN;
14. Sufficient pulmonary function defined by indoor oxygen saturation≥92%;
15. With single or venous blood collection standards, and no other cell collectioncontraindications;
16. Ability and willingness to adhere to the study visit schedule and all protocolrequirements.

Exclusion Criteria:

1. Previous history of other malignancy;
2. Presence of uncontrolled active infection;
3. Evidence of disorder that need the treatment by glucocorticoids;
4. Active or chronic GVHD
5. The patients treatment by inhibitor of T cell
6. Pregnant or breasting-feeding women;
7. Any situation that investigators regard not suitable for attending in this study (e.g.HIV , HCVinfection or intravenous drug addiction) or may affect the data analysis.